Patents Examined by Brenda L. Coleman
  • Patent number: 11124511
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: September 21, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao
  • Patent number: 11124513
    Abstract: The present invention relates to avibactam free acid, a method for preparing avibactam free acid and a method for preparing avibactam sodium by further reacting avibactam free acid. The invention further refers to a pharmaceutical composition comprising avibactam free acid, one or more alkaline sodium salt(s) and one or more beta-lactam antibiotic(s). The pharmaceutical composition of the present invention can be used as medicament, in particular for treatment and/or prevention of bacterial infections.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: September 21, 2021
    Assignee: Sandoz AG
    Inventors: Michael Fischer, Andreas Lechner, Brigitte Staggl
  • Patent number: 11124493
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: September 21, 2021
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Patent number: 11117905
    Abstract: The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 14, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: James Francis Callahan, Roderick S. Davis, Nicole Cathleen Goodwin, Jeffrey K. Kerns
  • Patent number: 11111219
    Abstract: The invention describes the pyrimidine-based compounds of the general formula I. Described compounds lower the production of the prostaglandin E2. In concentrations lowering production of this factor by 50%, these compounds have no negative effect on the cell viability and they are not cytotoxic. Furthermore, the method of production of the compounds of the general formula I is provided. A pharmaceutical composition comprising the polysubstituted pyrimidines according to the invention and the use of these compounds for the treatment of the inflammatory diseases are also provided.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: September 7, 2021
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.
    Inventors: Viktor Kolman, Filip Kalcic, Zlatko Janeba, Zdenek Zidek
  • Patent number: 11111249
    Abstract: A heteroaryl-pyrazole derivative, and a preparation method therefor and a medical application thereof are described. Specifically, a new heteroaryl-pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, and a use of the derivative as a therapeutic agent, in particular as a TLR7 agonist, are described. The substituents in formula (I) have the same definitions as in the description.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 7, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Guobao Zhang, Dianqiang Ma, Huiqing Yuan, Feng He, Weikang Tao
  • Patent number: 11104670
    Abstract: Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: August 31, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Cornelia Dorner-Ciossek, Roland Pfau, Dieter Wiedenmayer
  • Patent number: 11104681
    Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: August 31, 2021
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
  • Patent number: 11104702
    Abstract: A process for the preparation of obeticholic acid and derivatives thereof by: (a) hydrogenation of the double bond and reductive opening of the epoxide of a compound of formula (II) or a salt or solvate thereof to obtain a compound of formula (IIIa) and/or (IIIb), or salts or solvates thereof and (b) conversion of a compound of formula (IIIa) and/or a compound of formula (IIIb), or a salt or solvate thereof, into a compound of formula (I), or a salt or solvate thereof
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: August 31, 2021
    Assignee: CRYSTAL PHARMA, S.A.U.
    Inventors: Ignacio Herráiz Sierra, Yolanda Fernández Sainz, Carlos Cordovilla Losada, Alfonso Pérez Encabo, José Angel Turiel Hernandez
  • Patent number: 11098047
    Abstract: The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals. In some embodiments, the present disclosure provides a compound of Formula (I) or tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 24, 2021
    Assignee: BIOVERSYS AG
    Inventors: Erin M. Duffy, Ashoke Bhattacharjee, Zoltan F. Kanyo, Joseph A. Ippolito
  • Patent number: 11091462
    Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs including an anti-tumour drug.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: August 17, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • Patent number: 11091446
    Abstract: Methods of selectively forming substituted pyrazines are provided. Methods of the present invention can include receiving a reaction solution including at least one carbon source and at least one nitrogen source, and heating the reaction solution to a reaction temperature and holding the reaction solution at the reaction temperature for a time sufficient to produce a reaction product comprising at least one substituted pyrazine. The carbon source can be selected from the group consisting of hydroxy ketone(s), sugar(s) treated with at least one buffer, and combinations thereof. Tobacco products incorporating substituted pyrazines are also provided.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: August 17, 2021
    Assignee: R.J. Reynolds Tobacco Company
    Inventors: Michael Francis Dube, William Monroe Coleman, III
  • Patent number: 11091492
    Abstract: The invention provides substituted pyrazolo[1,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[1,5-a]pyrimidine compounds described herein include 5,7-dimethyl-N-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide compounds and variants thereof.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: August 17, 2021
    Assignee: Bial—R&D Investments, S.A.
    Inventors: Renato T. Skerlj, Peter T. Lansbury, Andrew C. Good, Elyse Marie Josee Bourque
  • Patent number: 11091435
    Abstract: The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: August 17, 2021
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Anthony C. Blackburn, Ryan O. Castro, Mark Allen Hadd, You-An Ma, Antonio Garrido Montalban, Jaimie Karyn Rueter, Lee Alani Selvey, Sagar Raj Shakya, Marlon Carlos
  • Patent number: 11091466
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include comprising of Formula (I): (I) wherein A, D and Q are described herein.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: August 17, 2021
    Assignee: CARDIO THERAPEUTICS PTY LTD
    Inventors: Herbert Treutlein, Jun Zeng, Ian Dixon, Ian James, James T. Palmer
  • Patent number: 11084824
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 10, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Patent number: 11084826
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 10, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • Patent number: 11078216
    Abstract: The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: August 3, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: James Francis Callahan, Vincent J. Colandrea, Anthony William James Cooper, Nicole Cathleen Goodwin, Chelsea Ariane Huff, Joel Karpiak, Jeffrey K. Kerns, Hong Nie
  • Patent number: 11078204
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: August 3, 2021
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • Patent number: 11072607
    Abstract: The invention provides novel compounds having RIP1 kinase inhibitory activity, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 27, 2021
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton